Impaired Cardiac AMPK (5'-Adenosine Monophosphate-Activated Protein Kinase) and Ca
AMPK
action potential
calcium handling
ibrutinib
ventricular arrhythmias
Journal
Journal of the American Heart Association
ISSN: 2047-9980
Titre abrégé: J Am Heart Assoc
Pays: England
ID NLM: 101580524
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
medline:
6
6
2024
pubmed:
6
6
2024
entrez:
6
6
2024
Statut:
aheadofprint
Résumé
We recently demonstrated that acute administration of ibrutinib, a Bruton's tyrosine kinase inhibitor used in chemotherapy for blood malignancies, increases ventricular arrhythmia (VA) vulnerability. A pathway of ibrutinib-induced vulnerability to VA that can be modulated for cardioprotection remains unclear. The effects of ibrutinib on cardiac electrical activity and Ca VA vulnerability inflicted by ibrutinib may be mediated in part by an impairment of myocardial AMPK activity. Pharmacological activation of AMPK may be a protective strategy against ibrutinib-induced cardiotoxicity.
Sections du résumé
BACKGROUND
BACKGROUND
We recently demonstrated that acute administration of ibrutinib, a Bruton's tyrosine kinase inhibitor used in chemotherapy for blood malignancies, increases ventricular arrhythmia (VA) vulnerability. A pathway of ibrutinib-induced vulnerability to VA that can be modulated for cardioprotection remains unclear.
METHODS AND RESULTS
RESULTS
The effects of ibrutinib on cardiac electrical activity and Ca
CONCLUSIONS
CONCLUSIONS
VA vulnerability inflicted by ibrutinib may be mediated in part by an impairment of myocardial AMPK activity. Pharmacological activation of AMPK may be a protective strategy against ibrutinib-induced cardiotoxicity.
Identifiants
pubmed: 38842296
doi: 10.1161/JAHA.123.032357
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM